350 related articles for article (PubMed ID: 7579726)
41. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract][Full Text] [Related]
42. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
43. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
44. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
45. The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells.
Soltermann A; Ernst A; Leroy D; Stahel RA; Gasser SM
Exp Cell Res; 1999 Jun; 249(2):308-19. PubMed ID: 10366430
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
47. Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase II alpha phosphorylation.
Constantinou AI; Vaughan AT; Yamasaki H; Kamath N
Cancer Res; 1996 Sep; 56(18):4192-9. PubMed ID: 8797591
[TBL] [Abstract][Full Text] [Related]
48. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
49. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
[TBL] [Abstract][Full Text] [Related]
50. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II.
Mirski SE; Gerlach JH; Cole SP
Exp Cell Res; 1999 Sep; 251(2):329-39. PubMed ID: 10471318
[TBL] [Abstract][Full Text] [Related]
51. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
52. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
53. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
54. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
55. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
56. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
[TBL] [Abstract][Full Text] [Related]
57. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
Fernandes DJ; Qiu J; Catapano CV
Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
[TBL] [Abstract][Full Text] [Related]
58. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
59. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
[TBL] [Abstract][Full Text] [Related]
60. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
